Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study with Community Oncology Cancer Patients

Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study With Community Oncology Cancer Patients Charles L. Bennett, Elizabeth A. Calhoun Oncologist 2007; 12: 478-483 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the definitions of direct and indirect costs of medical care. Describe the feasibility of obtaining information on direct and indirect medical costs associated with febrile neutropenia. Identify clinical and nonclinical factors that are associated with larger estimates of direct and indirect medical costs for febrile neutropenia. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 30, 2007 Most Recent Review: Apr. 30, 2007* Most Recent Update: Apr. 30, 2007 Date Credit Expires: Apr. 30, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course